Home > Formulary : Paediatric > Paediatric Chapters > 2. Cardiovascular system >
BNSSG Paediatric Joint Formulary
2.1 Arrhythmias
Last edited: 03-09-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
2.1 Arrhythmias
Secondary Care to maintain responsibility for monitoring amber specialist initiated drugs in the cardiovascular section of the Paediatric formulary. A clear management plan detailed in the clinic letter is required to support primary care prescribing. GP Practices should ensure a plan is in place before taking over prescribing responsibility
Antiarrhythmics
Digoxin (oral) (TLS Amber specialist initiated)
Sotalol (oral) (TLS Amber)
Verapamil (oral) (TLS Amber)
Amiodarone (oral) (TLS Amber)
Flecainide (oral) (TLS Amber specialist initiated)
- Patients should contact the cardiac consultant secretary if they are experiencing a breakthrough of symptoms for necessary monitoring. Routine monitoring and review is dependent on the patient’s clinical situation and plan which will be detailed in the clinic letter. GP Practice to ensure a plan is in place before taking over prescribing responsibility.
- For further flecainide guidance click here
Adenosine (TLS Red)
Amiodarone (intravenous) (TLS Red)
- As per internal UHBW policy
Flecainide (intravenous) (TLS Red)
Lidocaine (TLS Red)
Magnesium sulphate - See Chapter 9.6 (TLS Red)
Mexiletine (TLS Red)
Propafenone (intravenous) (TLS Red)
Ajmaline (Unlicensed) (TLS Red)
- Approved for use in the diagnosis of Brugada syndrome by Consultant Cardiologists only
- BRCH guideline
Digoxin-specific antibody
Digoxin-specific antibody fragments (TLS Red)
- Reversal of life-threatening Digoxin overdose